Publications by authors named "G Schreil"
Article Synopsis
- This study evaluates the use of durvalumab combined with platinum and gemcitabine for treating biliary tract cancers, aiming to validate previous trial results in a real-world setting and investigate how molecular profiles may affect patient outcomes.* -
- The analysis involved 102 patients from multiple cancer centers, revealing a 71.57% disease control rate and a median overall survival of 13.61 months, with younger patients showing better outcomes.* -
- Findings indicate that while no specific molecular profiles predicted better responses to durvalumab, patients receiving tailored second-line therapy showed a potential survival advantage, highlighting the need for further research in this area.*
Background: Biliary tract cancers (BTCs) exhibit high mortality rates and significant heterogeneity in both clinical and molecular characteristics. This study aims to molecularly characterize a cohort of patients with BTC, with a specific focus on genomic alterations within homologous recombination repair (HRR) genes in a real-world setting.
Patients And Methods: We carried out a retrospective analysis on 256 patients with BTC treated at five Austrian centers and one German comprehensive cancer center between 2016 and 2023 utilizing comprehensive genomic profiling platforms to assess HRR status and its correlation with clinical outcomes after platinum-based chemotherapy.
Biliary tract cancers are rare cancers with poor prognosis due to a lack of therapeutic options, especially after the failure of first-line systemic treatment. Targeted treatments for this clinical situation are promising and have entered clinical practice. We aimed to describe the overall survival of matched targeted treatment after first-line treatment in patients with biliary tract cancers in an Austrian real-world multicenter cohort.
View Article and Find Full Text PDFThe experimental gingivitis model was used to compare the anti-plaque, anti-gingivitis and anti-microbial efficacies of a phenolic compound (Listerine) and an amine/stannous fluoride mouthwash (Meridol), using a placebo preparation as negative control and a chlorhexidine solution as positive control in a double-blind study. After professional toothcleaning, 36 volunteers performed optimal oral hygiene for a period of 2 weeks. They then ceased all oral hygiene procedures for 21 days during which they rinsed twice daily with 1 of the 4 mouthrinses.
View Article and Find Full Text PDF